99 Episoder

  1. Targeted therapy for BRAF-mutant pediatric glioma

    Publisert: 17.6.2022

  2. Early/evolving IDH wild-type glioblastoma

    Publisert: 20.5.2022

  3. PI3K signaling in IDH mutant gliomas

    Publisert: 6.5.2022

  4. Cell-free DNA from CSF in pediatric, adolescent and young adult patients

    Publisert: 22.4.2022

  5. Molecular determinants of neurocognitive deficits in glioma

    Publisert: 8.4.2022

  6. H3K27M cell-free tumor DNA tracking in response to ONC201 treatment for diffuse midline glioma

    Publisert: 25.3.2022

  7. Clinical trial accrual for women and minorities in neuro-oncology

    Publisert: 11.3.2022

  8. The clinical utility of next generation sequencing for IDHwt glioblastoma

    Publisert: 11.2.2022

  9. Trabectedin for recurrent grade 2 or 3 meningiomas

    Publisert: 28.1.2022

  10. Glioblastoma cell heterogeneity and plasticity

    Publisert: 14.1.2022

  11. Moleculary integrated grading for meningioma

    Publisert: 24.12.2021

  12. BOLD fMRI in IDH mutant gliomas

    Publisert: 10.12.2021

  13. Glioblastoma subtypes and response to Dasatinib

    Publisert: 26.11.2021

  14. Resection for recurrent brain metastases

    Publisert: 12.11.2021

  15. Incidental Meningiomas

    Publisert: 29.10.2021

  16. Immunosuppression in IDH mutant gliomas

    Publisert: 15.10.2021

  17. Immunotherapy for melanoma brain metastases

    Publisert: 1.10.2021

  18. DNA methylation profiles within the CATNON trial

    Publisert: 17.9.2021

  19. 18F FET PET in childhood CNS tumors

    Publisert: 3.9.2021

  20. Checkpoint blockade in atypical meningiomas

    Publisert: 20.8.2021

4 / 5

Neuro-Oncology: The Podcast will keep you up to date about the latest advances in the field as we present conversations with the authors of selected papers from Neuro-Oncology and its sister journals, Neuro-Oncology Practice and Neuro-Oncology Advances.

Visit the podcast's native language site